Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	COVID-19: Daily Top 10 Papers

Breast Cancer

Free Subscription Articles published in JAMA Retrieve available abstracts of 80 articles: HTML format

Single Articles

February 2021
1. MOURAD MS
   Donning and Doffing.
   JAMA. 2021;325:536.
   PubMed    
   
   
   December 2020
2. PARSONS HA, Burstein HJ
   Adjuvant Capecitabine in Triple-Negative Breast Cancer: New Strategies for Tailoring Treatment Recommendations.
   JAMA. 2020 Dec 10. pii: 2774294. doi: 10.1001/jama.2020.23371.
   PubMed    
   
   
   
3. WANG X, Wang SS, Huang H, Cai L, et al
   Effect of Capecitabine Maintenance Therapy Using Lower Dosage and Higher Frequency vs Observation on Disease-Free Survival Among Patients With Early-Stage Triple-Negative Breast Cancer Who Had Received Standard Treatment: The SYSUCC-001 Randomized Cli
   JAMA. 2020 Dec 10. pii: 2774295. doi: 10.1001/jama.2020.23370.
   PubMed     Abstract available
   
   
   November 2020
4. SLOMSKI A
   Long-term Mortality Outcomes in Early Breast Cancer Screening Trial.
   JAMA. 2020;324:2020.
   PubMed    
   
   
   September 2020
5. HAMPTON T
   RNA Aptamers Deliver Chemotherapy Directly to Tumors.
   JAMA. 2020;324:829.
   PubMed    
   
   
   August 2020
6. VOELKER R
   Breast Cancer Drug Can Be Given at Home or in the Clinic.
   JAMA. 2020;324:433.
   PubMed    
   
   
   July 2020
7. CHLEBOWSKI RT, Anderson GL, Aragaki AK, Manson JE, et al
   Association of Menopausal Hormone Therapy With Breast Cancer Incidence and Mortality During Long-term Follow-up of the Women's Health Initiative Randomized Clinical Trials.
   JAMA. 2020;324:369-380.
   PubMed     Abstract available
   
   
   
8. KURIAN AW, Bernhisel R, Stefanick ML
   Pathogenic Variants in Breast Cancer Susceptibility Genes in Older Women-Reply.
   JAMA. 2020;324:397-398.
   PubMed    
   
   
   
9. FOSTIRA F, Kalfakakou D, Konstantopoulou I
   Pathogenic Variants in Breast Cancer Susceptibility Genes in Older Women.
   JAMA. 2020;324:397.
   PubMed    
   
   
   
10. MINAMI CA, Freedman RA
    Menopausal Hormone Therapy and Long-term Breast Cancer Risk: Further Data From the Women's Health Initiative Trials.
    JAMA. 2020;324:347-349.
    PubMed    
    
    
    
11. GRAHAM D, DiNome ML, Ganz PA
    Breast Cancer Risk-Reducing Medications.
    JAMA. 2020;324:310.
    PubMed    
    
    
    
12. SHIEH Y, Tice JA
    Medications for Primary Prevention of Breast Cancer.
    JAMA. 2020;324:291-292.
    PubMed    
    
    
    June 2020
13. VOELKER R
    Triple-Negative Breast Cancer Drug Receives Approval.
    JAMA. 2020;323:2122.
    PubMed    
    
    
    March 2020
14. RUBIN R
    White Blood Cells Might Provide Clues to Breast Cancer Risk.
    JAMA. 2020;323:1123.
    PubMed    
    
    
    
15. KURIAN AW, Bernhisel R, Larson K, Caswell-Jin JL, et al
    Prevalence of Pathogenic Variants in Cancer Susceptibility Genes Among Women With Postmenopausal Breast Cancer.
    JAMA. 2020;323:995-997.
    PubMed    
    
    
    February 2020
16. COMSTOCK CE, Gatsonis C, Newstead GM, Snyder BS, et al
    Comparison of Abbreviated Breast MRI vs Digital Breast Tomosynthesis for Breast Cancer Detection Among Women With Dense Breasts Undergoing Screening.
    JAMA. 2020;323:746-756.
    PubMed     Abstract available
    
    
    
17. TOSTESON ANA
    An Abbreviated MRI Protocol for Breast Cancer Screening in Women With Dense Breasts: Promising Results, but Further Evaluation Required Prior to Widespread Implementation.
    JAMA. 2020;323:719-721.
    PubMed    
    
    
    
18. QUAGLIARELLO V
    Tiny Branches.
    JAMA. 2020;323:711-712.
    PubMed    
    
    
    
19. COMSTOCK CE, Gatsonis C, Newstead GM, Snyder BS, et al
    Comparison of Abbreviated Breast MRI vs Digital Breast Tomosynthesis for Breast Cancer Detection Among Women With Dense Breasts Undergoing Screening.
    JAMA. 2020;323:746-756.
    PubMed     Abstract available
    
    
    
20. ABBASI J
    Artificial Intelligence Improves Breast Cancer Screening in Study.
    JAMA. 2020;323:499.
    PubMed    
    
    
    
21. VOELKER R
    Another Targeted Therapy for ERBB2-Positive Breast Cancer.
    JAMA. 2020;323:408.
    PubMed    
    
    
    January 2020
22. KRIST AH, Owens DK, Mangione CM
    Recommendations Related to Genetic Testing for Breast Cancer-Reply.
    JAMA. 2020;323:188-189.
    PubMed    
    
    
    
23. PINSKY PF
    Recommendations Related to Genetic Testing for Breast Cancer.
    JAMA. 2020;323:187-188.
    PubMed    
    
    
    
24. DORK T, Park-Simon TW, Hillemanns P
    Recommendations Related to Genetic Testing for Breast Cancer.
    JAMA. 2020;323:188.
    PubMed    
    
    
    
25. SLAVIN SD
    Doctoring and Deportation.
    JAMA. 2020;323:119-120.
    PubMed    
    
    
    December 2019
26. FAYANJU OLM
    Hiding in Plain Sight.
    JAMA. 2019;322:2173-2174.
    PubMed    
    
    
    September 2019
27. SLOMSKI A
    Adjuvant Therapy for HER2-Positive Breast Cancer.
    JAMA. 2019;322:1134.
    PubMed    
    
    
    
28. OWENS DK, Davidson KW, Krist AH, Barry MJ, et al
    Medication Use to Reduce Risk of Breast Cancer: US Preventive Services Task Force Recommendation Statement.
    JAMA. 2019;322:857-867.
    PubMed     Abstract available
    
    
    
29. NELSON HD, Fu R, Zakher B, Pappas M, et al
    Medication Use for the Risk Reduction of Primary Breast Cancer in Women: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.
    JAMA. 2019;322:868-886.
    PubMed     Abstract available
    
    
    
30. JIN J
    Medications to Reduce Breast Cancer Risk.
    JAMA. 2019;322:900.
    PubMed    
    
    
    
31. PACE LE, Keating NL
    Medications to Reduce Breast Cancer Risk: Promise and Limitations.
    JAMA. 2019;322:821-823.
    PubMed    
    
    
    August 2019
32. IZZO MC, Bronner G, Shields CL
    Rapidly Progressive Vision Loss in a Patient With Breast Cancer.
    JAMA. 2019 Aug 22. pii: 2749078. doi: 10.1001/jama.2019.12691.
    PubMed    
    
    
    
33. OWENS DK, Davidson KW, Krist AH, Barry MJ, et al
    Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer: US Preventive Services Task Force Recommendation Statement.
    JAMA. 2019;322:652-665.
    PubMed     Abstract available
    
    
    
34. NELSON HD, Pappas M, Cantor A, Haney E, et al
    Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer in Women: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.
    JAMA. 2019;322:666-685.
    PubMed     Abstract available
    
    
    
35. JIN J
    Should I Be Tested for BRCA Mutations?
    JAMA. 2019;322:702.
    PubMed    
    
    
    July 2019
36. SLOMSKI A
    Preventing Cardiotoxicity Associated With Breast Cancer Therapy.
    JAMA. 2019;322:296.
    PubMed    
    
    
    
37. 
    First PI3K Inhibitor for Breast Cancer.
    JAMA. 2019;322:19.
    PubMed    
    
    
    
38. CHOI JM
    An Unexpected Asset.
    JAMA. 2019;322:29.
    PubMed    
    
    
    June 2019
39. KEATING NL, Pace LE
    New Federal Requirements to Inform Patients About Breast Density: Will They Help Patients?
    JAMA. 2019;321:2275-2276.
    PubMed    
    
    
    May 2019
40. KERLIKOWSKE K, Miglioretti DL, Vachon CM
    Discussions of Dense Breasts, Breast Cancer Risk, and Screening Choices in 2019.
    JAMA. 2019 May 31. pii: 2735405. doi: 10.1001/jama.2019.6247.
    PubMed    
    
    
    
41. CRANDALL CJ, Livingston E
    Women's Health: A New JAMA Clinical Insights Series.
    JAMA. 2019;321:1676.
    PubMed    
    
    
    
42. POLITE BN, Gluck AR, Brawley OW
    Ensuring Equity and Justice in the Care and Outcomes of Patients With Cancer.
    JAMA. 2019;321:1663-1664.
    PubMed    
    
    
    April 2019
43. RUDDY KJ, Ganz PA
    Treatment of Nonmetastatic Breast Cancer.
    JAMA. 2019 Apr 12. pii: 2731086. doi: 10.1001/jama.2019.3927.
    PubMed    
    
    
    
44. VOELKER R
    Quick Uptakes: Taking the Uncertainty Out of Interpreting BRCA Variants.
    JAMA. 2019;321:1340-1341.
    PubMed    
    
    
    February 2019
45. SLOMSKI A
    BMI Not a Good Proxy for Breast Cancer Risk.
    JAMA. 2019;321:735.
    PubMed    
    
    
    January 2019
46. WAKS AG, Winer EP
    Breast Cancer Treatment: A Review.
    JAMA. 2019;321:288-300.
    PubMed     Abstract available
    
    
    
47. WAKS AG, Winer EP
    Breast Cancer Treatment.
    JAMA. 2019;321:316.
    PubMed    
    
    
    
48. DOMCHEK SM
    Risk-Reducing Mastectomy in BRCA1 and BRCA2 Mutation Carriers: A Complex Discussion.
    JAMA. 2019;321:27.
    PubMed    
    
    
    December 2018
49. SLOMSKI A
    Chemoimmunotherapy for Triple-Negative Breast Cancer.
    JAMA. 2018;320:2521.
    PubMed    
    
    
    
50. HERSHMAN DL, Unger JM, Crew K
    Acupuncture for Aromatase Inhibitor-Related Joint Pain Among Breast Cancer Patients.
    JAMA. 2018;320:2270-2271.
    PubMed    
    
    
    
51. LIU C, Zhang H, Sun C
    Acupuncture for Aromatase Inhibitor-Related Joint Pain Among Breast Cancer Patients.
    JAMA. 2018;320:2270.
    PubMed    
    
    
    
52. MAO JJ, Farrar JT
    Acupuncture for Aromatase Inhibitor-Related Joint Pain Among Breast Cancer Patients.
    JAMA. 2018;320:2269-2270.
    PubMed    
    
    
    August 2018
53. LEE GK, Sheckter CC
    Breast Reconstruction Following Breast Cancer Treatment-2018.
    JAMA. 2018 Aug 31. pii: 2701789. doi: 10.1001/jama.2018.12190.
    PubMed    
    
    
    
54. GROSS AL, Blot WJ, Visvanathan K
    BRCA1 and BRCA2 Testing in Medically Underserved Medicare Beneficiaries With Breast or Ovarian Cancer.
    JAMA. 2018;320:597-598.
    PubMed    
    
    
    
55. ABBASI J
    Can Acupuncture Keep Women on Their Breast Cancer Drugs?
    JAMA. 2018 Aug 8. pii: 2696922. doi: 10.1001/jama.2018.11068.
    PubMed    
    
    
    July 2018
56. SLOMSKI A
    Many Women With Early Breast Cancer May Not Need Chemotherapy.
    JAMA. 2018;320:332.
    PubMed    
    
    
    
57. HERSHMAN DL, Unger JM, Greenlee H, Capodice JL, et al
    Effect of Acupuncture vs Sham Acupuncture or Waitlist Control on Joint Pain Related to Aromatase Inhibitors Among Women With Early-Stage Breast Cancer: A Randomized Clinical Trial.
    JAMA. 2018;320:167-176.
    PubMed     Abstract available
    
    
    
58. ABBASI J
    Immunotherapy Leads to Complete Regression in Late-Stage Breast Cancer.
    JAMA. 2018;320:127.
    PubMed    
    
    
    June 2018
59. GILL J, Obley AJ, Prasad V
    Direct-to-Consumer Genetic Testing: The Implications of the US FDA's First Marketing Authorization for BRCA Mutation Testing.
    JAMA. 2018;319:2377-2378.
    PubMed    
    
    
    
60. PLEVRITIS SK, Berry DA, Mandelblatt JS
    Contributions of Screening and Treatment to Mortality From Breast Cancer-Reply.
    JAMA. 2018;319:2336.
    PubMed    
    
    
    
61. CHEN HH
    Contributions of Screening and Treatment to Mortality From Breast Cancer.
    JAMA. 2018;319:2335-2336.
    PubMed    
    
    
    May 2018
62. KEATING NL, Pace LE
    Breast Cancer Screening in 2018: Time for Shared Decision Making.
    JAMA. 2018;319:1814-1815.
    PubMed    
    
    
    April 2018
63. BEJNORDI BE, Litjens G, van der Laak JA
    Machine Learning Compared With Pathologist Assessment-Reply.
    JAMA. 2018;319:1726.
    PubMed    
    
    
    
64. VAN SMEDEN M, Van Calster B, Groenwold RHH
    Machine Learning Compared With Pathologist Assessment.
    JAMA. 2018;319:1725-1726.
    PubMed    
    
    
    March 2018
65. KATZ SJ, Jagsi R, Morrow M
    Reducing Overtreatment of Cancer With Precision Medicine: Just What the Doctor Ordered.
    JAMA. 2018;319:1091-1092.
    PubMed    
    
    
    February 2018
66. PEACHMAN RR
    Weighing the Risks and Benefits of Hormonal Contraception.
    JAMA. 2018 Feb 28. pii: 2673941. doi: 10.1001/jama.2018.0448.
    PubMed    
    
    
    
67. HENNEMAN JR
    In Shadow and Light-Images of Transformation Through Breast Cancer.
    JAMA. 2018;319:532-534.
    PubMed    
    
    
    January 2018
68. BALLMAN KV, McCall LM, Giuliano AE
    Axillary vs Sentinel Lymph Node Dissection in Women With Invasive Breast Cancer-Reply.
    JAMA. 2018;319:306-307.
    PubMed    
    
    
    
69. UNO H, Hassett MJ, Wei LJ
    Axillary vs Sentinel Lymph Node Dissection in Women With Invasive Breast Cancer.
    JAMA. 2018;319:306.
    PubMed    
    
    
    
70. PLEVRITIS SK, Munoz D, Kurian AW, Stout NK, et al
    Association of Screening and Treatment With Breast Cancer Mortality by Molecular Subtype in US Women, 2000-2012.
    JAMA. 2018;319:154-164.
    PubMed     Abstract available
    
    
    
71. MANSON JE, Aragaki AK, Rossouw JE
    Menopausal Estrogen Therapy and Breast Cancer Mortality-Reply.
    JAMA. 2018;319:193-194.
    PubMed    
    
    
    
72. HICKEY M, McNamara HC, Mishra GD
    Menopausal Estrogen Therapy and Breast Cancer Mortality.
    JAMA. 2018;319:193.
    PubMed    
    
    
    December 2017
73. EHTESHAMI BEJNORDI B, Veta M, Johannes van Diest P, van Ginneken B, et al
    Diagnostic Assessment of Deep Learning Algorithms for Detection of Lymph Node Metastases in Women With Breast Cancer.
    JAMA. 2017;318:2199-2210.
    PubMed     Abstract available
    
    
    
74. GOLDEN JA
    Deep Learning Algorithms for Detection of Lymph Node Metastases From Breast Cancer: Helping Artificial Intelligence Be Seen.
    JAMA. 2017;318:2184-2186.
    PubMed    
    
    
    November 2017
75. ENGELHARDT KE, Barnard C, Bilimoria KY
    Wrong-Site Surgery.
    JAMA. 2017;318:2033-2034.
    PubMed    
    
    
    
76. THOMAS R, Fysh ETH, Smith NA, Lee P, et al
    Effect of an Indwelling Pleural Catheter vs Talc Pleurodesis on Hospitalization Days in Patients With Malignant Pleural Effusion: The AMPLE Randomized Clinical Trial.
    JAMA. 2017;318:1903-1912.
    PubMed     Abstract available
    
    
    September 2017
77. SLOMSKI A
    Low-Fat Diet Reduces Mortality After Breast Cancer.
    JAMA. 2017;318:1099.
    PubMed    
    
    
    
78. GIULIANO AE, Ballman KV, McCall L, Beitsch PD, et al
    Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival Among Women With Invasive Breast Cancer and Sentinel Node Metastasis: The ACOSOG Z0011 (Alliance) Randomized Clinical Trial.
    JAMA. 2017;318:918-926.
    PubMed     Abstract available
    
    
    
79. LIVINGSTON EH, Li HC
    Breast Cancer Surgery: Less Is More.
    JAMA. 2017;318:909-911.
    PubMed    
    
    
    
80. MCNEIL M
    Menopausal Hormone Therapy: Understanding Long-term Risks and Benefits.
    JAMA. 2017;318:911-913.
    PubMed    
    
    

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: